Market Overview

Morgan Stanley Reiterates Equal-Weight Rating on Sagent Pharmaceuticals

Related SGNT
15 Biggest Mid-Day Gainers For Tuesday
Benzinga's Volume Movers

In a report published Monday, Morgan Stanley reiterated its Equal-Weight rating on Sagent Pharmaceuticals (NASDAQ: SGNT).

Morgan Stanley noted, “Total November IMS sales were $17MM establishing a 4Q12 run rate of $53MM in-line with MSe and Cns of $52MM and guidance of ~$50MM. However, the focus is now on 2013 commercial momentum and we are comfortable with our $227MM estimate for 2013 (consensus of $243MM) driven by new launches and firming base business performance.”

Sagent Pharmaceuticals closed on Friday at $15.70.

Latest Ratings for SGNT

Jul 2016RBC CapitalDowngradesOutperformSector Perform
Jun 2016JefferiesMaintainsHold
Jan 2016Deutsche BankMaintainsBuy

View More Analyst Ratings for SGNT
View the Latest Analyst Ratings

Posted-In: Morgan StanleyAnalyst Color Reiteration Analyst Ratings


Related Articles (SGNT)

View Comments and Join the Discussion!

Partner Center